Open AccessBleomycin induced flagellate erythema: Revisiting a unique complication
Author(s) -
Ahitagni Biswas,
Pritee Chaudhari,
Punit Sharma,
Lavleen Singh,
Pramod Kumar Julka,
Gomathy Sethuraman
Publication year - 2013
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.119358
Subject(s) - bleomycin , medicine , dermatology , rash , abvd , complication , vinca , adverse effect , chemotherapy , surgery , pharmacology , vincristine , cyclophosphamide
Bleomycin induced flagellate dermatitis is a rare and unique adverse effect. With the declining use of bleomycin, this complication is becoming increasingly infrequent in common clinical practice. We herein describe a case of a 22-year-old Indian male with Hodgkin's lymphoma, Ann Arbor stage IIBEX developing flagellate dermatitis following 1(st) cycle of chemotherapy with ABVD regimen. The diagnostic dilemma in the illustrative case underscores the importance of awareness and prompt identification and treatment of this dermatological toxicity in limiting morbidity in patients undergoing bleomycin based combination chemotherapy. In patients having severe rash, bleomycin should be expeditiously discontinued. Omission of bleomycin does not compromise the treatment outcome in the majority of patients with Hodgkin's lymphoma.